BioCryst reports efficacy of HAE drug across age groups

BioCryst Pharmaceuticals (BCRX) announced positive data for its HAE treatment, berotralstat, demonstrating efficacy in reducing symptom days in children and maintaining a strong safety profile across all ages; the company's stock is trading near its 52-week high, reflecting investor confidence. Interim results from the APeX-P trial showed a reduction in symptom days from 11% to 4% over 12 weeks in children aged 2-11, with sustained improvements up to 48 weeks. Additionally, BioCryst reported strong Q1 2025 revenue driven by Orladeyo sales, leading to raised annual revenue guidance and expectations for full-year profitability in 2025, a year ahead of schedule.

Analysis

BioCryst Pharmaceuticals (NASDAQ:BCRX) has presented compelling new data for its hereditary angioedema (HAE) treatment, berotralstat, demonstrating significant efficacy in pediatric patients and a consistent safety profile across various age groups. The APeX-P trial's interim results showed a reduction in symptom days for children aged 2 to 11 from a pre-study baseline of 11 percent to 4 percent over 12 weeks, with improvements sustained up to 48 weeks and at least half remaining attack-free monthly; common adverse events were limited to nasopharyngitis and headache. This positive clinical development is complemented by strong financial performance, evidenced by a 41.67% revenue growth over the last twelve months and a robust gross profit margin of 64.25%. The company's stock is trading near its 52-week high of $11.11, reflecting investor optimism. Further reinforcing this sentiment, BioCryst reported Q1 2025 revenue of $145.5 million, surpassing the $127.9 million forecast, largely driven by Orladeyo (berotralstat) sales which reached $134 million, a 51% year-over-year increase. Earnings per share also outperformed expectations at $0.00, against a predicted loss of $0.07. Consequently, BioCryst has raised its annual revenue guidance for Orladeyo to between $580 million and $600 million and now anticipates achieving full-year profitability in 2025, a year earlier than previously expected, supported by strong sales and strategic debt reduction. Analyst sentiment is also favorable, with Jefferies maintaining a Buy rating and increasing its price target from $12.00 to $14.00, citing Orladeyo's performance and upcoming pipeline catalysts, including treatments for Netherton syndrome and diabetic macular edema. While ORLADEYO is not recommended for acute HAE attacks or at doses above 150 mg daily due to potential QT prolongation, its efficacy as a once-daily oral prophylactic for patients 12 years and older is well-established through studies like the Italian Expanded Access Program and the Berolife study in France.

Key Decisions for Investors

• Given the strong clinical data for berotralstat, robust Orladeyo sales growth, upwardly revised revenue guidance, and accelerated profitability timeline, investors may consider the current positive momentum supportive of a bullish stance on BCRX.
• Investors should closely monitor the company's progress towards achieving its revised 2025 full-year profitability target and watch for upcoming pipeline data updates for Netherton syndrome and diabetic macular edema, which represent potential significant value drivers.
• While the stock's proximity to its 52-week high reflects strong market confidence, continued execution on Orladeyo sales targets and successful pipeline advancements will be crucial for sustaining current valuation levels; the QT prolongation risk associated with higher doses of ORLADEYO, though within approved usage guidelines, remains a standard safety aspect to acknowledge.